Toward aNOTCH1/FBXW7/RAS/PTEN–Based Oncogenetic Risk Classification of Adult T-Cell Acute Lymphoblastic Leukemia: A Group for Research in Adult Acute Lymphoblastic Leukemia Study
Authors:
- Amélie TrinquandATAmélie Trinquand
- Aline Tanguy-SchmidtATAline Tanguy-Schmidt
- Raouf Ben AbdelaliRARaouf Ben Abdelali
- Jérôme LambertJLJérôme Lambert
- Kheira BeldjordKBKheira Beldjord
- Etienne LenglinéELEtienne Lengliné
- Noémie De GunzburgNGNoémie De Gunzburg
- Dominique Payet-BornetDPDominique Payet-Bornet
- Ludovic LhermitteLLLudovic Lhermitte
- Hossein MossafaHMHossein Mossafa
- Véronique LhéritierVLVéronique Lhéritier
- Jonathan BondJBJonathan Bond
- 1 December 2013
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 31 (34) , 4333-4342
Abstract
Purpose: The Group for Research in Adult Acute Lymphoblastic Leukemia (GRAALL) recently reported a significantly better outcome in T-cell acute lymphoblastic leukemia (T-ALL) harboring NOTCH1 and/or FBXW7 (N/F) mutations compared with unmutated T-ALL. Despite this, one third of patients with N/F-mutated T-ALL experienced relapse.Patients and Methods: In a series of 212 adult T-ALLs included in the multicenter randomized GRAALL-2003 and -2005 trials, we searched for additional N/K-RAS mutations and PTEN defects (mutations and gene deletion).Results: N/F mutations were identified in 143 (67%) of 212 patients, and lack of N/F mutation was confirmed to be associated with a poor prognosis. K-RAS, N-RAS, and PTEN mutations/deletions were identified in three (1.6%) of 191, 17 (8.9%) of 191, and 21 (12%) of 175 patients, respectively. The favorable prognostic significance of N/F mutations was restricted to patients without RAS/PTEN abnormalities. These observations led us to propose a new T-ALL oncogenetic classifier defining low-risk patients as those with N/F mutation but no RAS/PTEN mutation (97 of 189 patients; 51%) and all other patients (49%; including 13% with N/F and RAS/PTEN mutations) as high-risk patients. In multivariable analysis, this oncogenetic classifier remained the only significant prognostic covariate (event-free survival: hazard ratio [HR], 3.2; 95% CI, 1.9 to 5.15; P < .001; and overall survival: HR, 3.2; 95% CI, 1.9 to 5.6; P < .001).Conclusion: These data demonstrate that the presence of N/F mutations in the absence of RAS or PTEN abnormalities predicts good outcome in almost 50% of adult T-ALL. Conversely, the absence of N/F or presence of RAS/PTEN alterations identifies the remaining cohort of patients with poor prognosis.Keywords
This publication has 32 references indexed in Scilit:
- Exome sequencing identifies mutation in CNOT3 and ribosomal genes RPL5 and RPL10 in T-cell acute lymphoblastic leukemiaNature Genetics, 2012
- The molecular basis of T cell acute lymphoblastic leukemiaJournal of Clinical Investigation, 2012
- The genetic basis of early T-cell precursor acute lymphoblastic leukaemiaNature, 2012
- Pediatric-inspired intensified therapy of adult T-ALL reveals the favorable outcome of NOTCH1/FBXW7 mutations, but not of low ERG/BAALC expression: a GRAALL studyBlood, 2011
- Molecular pathogenesis of T-cell leukaemia and lymphomaNature Reviews Immunology, 2008
- FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to γ-secretase inhibitorsJournal of Experimental Medicine, 2007
- Treatment of Acute Lymphoblastic LeukemiaNew England Journal of Medicine, 2006
- HOXA genes are included in genetic and biologic networks defining human acute T-cell leukemia (T-ALL)Blood, 2005
- Activating Mutations of NOTCH1 in Human T Cell Acute Lymphoblastic LeukemiaScience, 2004
- Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemiaCancer Cell, 2002